Compare Neurocrine Biosciences Inc (NBIX) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Payoneer Global Inc — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while Payoneer Global Inc trades at $7.11 (market cap $2.42B). The key difference: Neurocrine Biosciences Inc is far larger — about 6.5× Payoneer Global Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | PAYO | |
|---|---|---|
Market Cap | $15.77B | $2.42B |
Sector | Health | Technology |
52-Week High | $185.50 | $7.18 |
52-Week Low | $123.10 | $4.27 |
Enterprise Value | $15.78B | $2.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Payoneer Global (PAYO) trades at $7.13, down 0.56% on the day, with a market cap of approximately $2.3 billion. The stock shows mixed technical signals with a bullish moving average trend but neutral oscillators. Fundamentally, revenue grew to $821 million in 2025 with a 79.4% gross margin, though net income margin declined to 5.83%. Recent news highlights the pending acquisition by Nuvei for $7.40 per share, with multiple law firms investigating the fairness of the deal price.
The acquisition offer at $7.40 provides near-term upside potential, but investor sentiment is cautious due to legal scrutiny. Long-term growth prospects remain positive with expanding global operations, though earnings volatility and competitive pressures present risks. Analyst consensus is bullish with 60% buy ratings, but the stock faces execution risks in integrating the India tech hub and maintaining B2B growth momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
